Top

Published in:

01-07-2011 | Original paper

Dietary carbohydrate, glycemic index, glycemic load, and risk of prostate cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO) cohort

Authors: James M. Shikany, Andrew P. Flood, Cari M. Kitahara, Ann W. Hsing, Tamra E. Meyer, Bradley J. Willcox, David T. Redden, Regina G. Ziegler

Published in: Cancer Causes & Control | Issue 7/2011

Abstract

Objective

To evaluate the associations between dietary carbohydrate, glycemic index (GI), glycemic load (GL), and incident prostate cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO) cohort.

Methods

Between September 1993 and September 2000, 38,343 men were randomized to the screening arm of the trial at one of 10 PLCO centers. A food frequency questionnaire administered at baseline assessed usual dietary intake over the preceding 12 months. Prostate cancer was ascertained by medical follow-up of suspicious screening results and annual mailed questionnaires and confirmed with medical records. Cox proportional hazards regression was used to model the associations of carbohydrate, GI, and GL with prostate cancer risk.

Results

During follow-up (median = 9.2 years), 2,436 incident prostate cancers were identified among 30,482 eligible participants. Overall, there were no associations of baseline carbohydrate, GI, or GL with incident prostate cancer in minimally or fully adjusted models. There were no associations when the 228 advanced and 2,208 non-advanced cancers were analyzed separately.

Conclusions

Dietary carbohydrate, GI, and GL were not associated with incident prostate cancer in PLCO. The narrow range of GI in this cohort may have limited our ability to detect associations, an issue that future studies should address.

World Cancer Research Fund/American Institute for Cancer Research (2007) Food, nutrition, physical activity, and the prevention of cancer: a global perspective. World Cancer Research Fund/American Institute for Cancer Research, Washington, DC

Jenkins DJ, Wolever TM, Taylor RH et al (1981) Glycemic index of foods: a physiological basis for carbohydrate exchange. Am J Clin Nutr 34:362–366PubMed

Wolever TM (1990) The glycaemic index. World Rev Nutr Diet 62:120–185PubMed

Liu S, Manson JE, Stampfer MJ et al (2001) Dietary glycemic load assessed by food-frequency questionnaire in relation to plasma high-density-lipoprotein cholesterol and fasting plasma triacylglycerols in postmenopausal women. Am J Clin Nutr 73:560–566PubMed

Biddinger SB, Ludwig DS (2005) The insulin-like growth factor axis: a potential link between glycemic index and cancer. Am J Clin Nutr 82:277–278PubMed

Jenkins DJ, Wolever TM, Collier GR et al (1987) Metabolic effects of a low-glycemic-index diet. Am J Clin Nutr 46:968–975PubMed

Plymate SR, Matej LA, Jones RE, Friedl KE (1988) Inhibition of sex hormone binding-globulin production in the human hepatoma (Hep G2) cell line by insulin and prolactin. J Clin Endocrinol Metab 67:460–464PubMedCrossRef

Castagnetta LA, Miceli MD, Sorci CM et al (1995) Growth of LNCaP human prostate cancer cells is stimulated by estradiol via its own receptor. Endocrinology 136:2309–2319PubMedCrossRef

Pollak M (2001) Insulin-like growth factors and prostate cancer. Epidemiol Rev 23:59–66PubMed

10.

Yu H, Rohan T (2000) Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 92:1472–1489PubMedCrossRef

11.

Gnagnarella P, Gandini S, La Vecchia C, Maisonneuve P (2008) Glycemic index, glycemic load, and cancer risk: a meta-analysis. Am J Clin Nutr 87:1793–1801PubMed

12.

Barclay AW, Petocz P, McMillan-Price J et al (2008) Glycemic index, glycemic load, and chronic disease risk–a meta-analysis of observational studies. Am J Clin Nutr 87:627–637PubMed

13.

Augustin LSA, Galeone C, Dal Maso L et al (2004) Glycemic index, glycemic load and risk of prostate cancer. Int J Cancer 112:446–450PubMedCrossRef

14.

George SM, Mayne ST, Leitzmann MF et al (2009) Dietary glycemic index, glycemic load, and risk of cancer: a prospective cohort study. Am J Epidemiol 169:462–472PubMedCrossRef

15.

Nimptsch K, Kenfield S, Jensen MK et al (2011) Dietary glycemic index, glycemic load, insulin index, fiber and whole-grain intake in relation to risk of prostate cancer. Cancer Causes Control 22:51–61PubMedCrossRef

16.

Pinsky PF, Kramer BS, Crawford ED et al (2006) Prostate volume and prostate-specific antigen levels in men enrolled in a large screening trial. Urology 68:352–356PubMedCrossRef

17.

Flood A, Peters U, Jenkins DJA, for the Prostate, Lung, Colorectal, Ovarian (PLCO) Project Team, et al (2006) Carbohydrate, glycemic index, and glycemic load and colorectal adenomas in the prostate, lung, colorectal, and ovarian screening study. Am J Clin Nutr 84:1184–1192

18.

Flood A, Subar AF, Hull SG, Zimmerman TP, Jenkins DJ, Schatzkin A (2006) Methodology for adding glycemic load values to the National Cancer Institute Diet History Questionnaire database. J Am Diet Assoc 106:393–402PubMedCrossRef

19.

Foster-Powell K, Holt SH, Brand-Miller JC (2002) International table of glycemic index and glycemic load values: 2002. Am J Clin Nutr 76:5–56PubMed

20.

Subar AF, Midthune D, Kulldorff M et al (2000) Evaluation of alternative approaches to assign nutrient values to food groups in food frequency questionnaires. Am J Epidemiol 152:279–286PubMedCrossRef

21.

U.S. Department of Agriculture, Agricultural Research Service (2005) USDA national nutrient database for standard reference, release 18. Nutrient data laboratory home page, http://www.nal.usda.gov/fnic/foodcomp

Title: Dietary carbohydrate, glycemic index, glycemic load, and risk of prostate cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO) cohort
Authors: James M. Shikany
Andrew P. Flood
Cari M. Kitahara
Ann W. Hsing
Tamra E. Meyer
Bradley J. Willcox
David T. Redden
Regina G. Ziegler
Publication date: 01-07-2011
Publisher: Springer Netherlands
Published in: Cancer Causes & Control / Issue 7/2011
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI: https://doi.org/10.1007/s10552-011-9772-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objective

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 7/2011

The association of diabetes mellitus and high-grade prostate cancer in a multiethnic biopsy series

Reconstruction of long-term tobacco consumption trends in Australia and their relationship to lung cancer mortality

Association between psoriasis and incident cancer: the Iowa’s Women’s Health Study

Alcohol and tobacco, and the risk of cancers of the upper aerodigestive tract in Latin America: a case–control study

Telomere length in peripheral blood and breast cancer risk in a prospective case-cohort analysis: results from the Sister Study

Commentary: Serum lycopene and prostate cancer progression: a re-consideration of findings from the prostate cancer prevention trial

Keynote webinar | Spotlight on antibody–drug conjugates in cancer